FDA warns Forest Labs about Bystolic ads

Forest Laboratories Inc. received a warning letter from the FDA near the end of August for failure to show the risks of its high blood pressure medication, Bystolic, when promoting the drug to physicians.

The company ran an eight-page ad in a variety of medical journals favorably comparing the medication to other medications, but without enough research to support their claims. The advertisements omitted and minimized some of the risks associated with the drug--including cardiac failure and chest pain, as well as claimed the drug was superior for use in patients with obesity, diabetes and poor metabolism--without sufficient evidence to do so, according to the FDA. 

Share prices also dropped following legal claims on the Bystolic patent.

- catch the Forbes.com story
- read the Pharmalot blog post

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.